Genzyme ends tracking-stock structure
Executive Summary
Genzyme will exchange shares of Genzyme Biosurgery stock and Genzyme Molecular Oncology stock for shares of Genzyme General stock on June 30. "We do not expect to make any major changes within our business or research programs at this time," CEO Henri Termeer says. Termeer was asked about the company's capital structure in light of concerns about tracking stocks and corporate accounting during an April 16 earnings call (1"The Pink Sheet" April 28, In Brief)...
You may also be interested in...
Genzyme reorganization?
Genzyme CEO Henri Termeer was asked several times during April 16 conference call about the company's capital structure in light of recent concerns about tracking stocks and corporate accounting. "We are always looking at the capital structure of the company. We are doing that now and will be looking at doing that in the future," Termeer says. Pressed for further comment, Termeer says, "this is an earnings call, not a structure call"...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.